Cross-national biologic treatment guidelines for FMF: a comparative analysis.

To examine cross-national accessibility and reimbursement policies for IL-1 inhibitors in FMF treatment and compare national guidelines. As part of the Clinical Practice Strategies (CLiPS) project, data on biologic DMARD (bDMARD) access and reimbursement were collected through q…

Criar conta gratuita para acessar o conteúdo completo